IGC Pharma (IGC Pharma) Net Margin % : -2,739.71% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. IGC Pharma's Net Income for the three months ended in Dec. 2023 was $-5.59 Mil. IGC Pharma's Revenue for the three months ended in Dec. 2023 was $0.20 Mil. Therefore, IGC Pharma's net margin for the quarter that ended in Dec. 2023 was -2,739.71%.

The historical rank and industry rank for IGC Pharma's Net Margin % or its related term are showing as below:

IGC' s Net Margin % Range Over the Past 10 Years
Min: -3782.37 Med: -156.32 Max: -44.1
Current: -1163.24

IGC's Net Margin % is ranked worse than
74.54% of 1029 companies
in the Biotechnology industry
Industry Median: -162.58 vs IGC: -1163.24

IGC Pharma Net Margin % Historical Data

The historical data trend for IGC Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Net Margin % Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Margin %

Get a 7-Day Free Trial

-80.08

-179.64

-981.18

-3,782.37

-1,263.01

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-677.41	-2,427.71	-373.87	-842.27	-2,739.71

Competitive Comparison of IGC Pharma's Net Margin %

For the Biotechnology subindustry, IGC Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Net Margin % falls into.

IGC Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

IGC Pharma's Net Margin for the fiscal year that ended in Mar. 2023 is calculated as

Net Margin	=	Net Income (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-11.506	/	0.911
	=	-1,263.01 %

IGC Pharma's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.589	/	0.204
	=	-2,739.71 %

IGC Pharma (AMEX:IGC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

IGC Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (IGC Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

IGS1:Germany

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Executives

James P Moran	director	914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch	director	14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins	director
Ram Mukunda	director, officer: Exec. Chairman & CEO
Claudia Grimaldi	officer: Vice president and PFO	PO BOX 60642, POTOMAC MD 20859
Rohit Goel	officer: Manager & PAO	PO BOX 60642, POTOMAC MD 20859
John Cherin	officer: CFO, Treasurer and PAO	662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai	director, officer: Interim CFO	4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna	director	330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy	director	10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani	director	INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd.	10 percent owner	C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii	10 percent owner	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs	10 percent owner	600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd.	10 percent owner	C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305